anti dr4 antibody (Proteintech)
Proteintech is a verified supplier 
93
Structured Review
Proteintech
anti dr4 antibody
Anti Dr4 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+dr4/DR4+Antibody/pmc13006433-10-0-3
Average 93 stars, based on 15 article reviews
Anti Dr4 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+dr4/DR4+Antibody/pmc13006433-10-0-3
Average 93 stars, based on 15 article reviews
anti dr4 antibody - by Bioz Stars,
2026-10
93/100 stars
Images
1) Product Images from "HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer"
Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
Journal: Cell Reports Medicine
doi: 10.1016/j.xcrm.2026.102630
Figure Legend Snippet: dDNMT activates TRAIL-death receptor signaling in VHL -deficient ccRCC cells (A) Volcano plot of SGI1027-induced and -repressed genes in RCC10 cells ( n = 2 biological replicates). FC, fold change. (B) Biocarta pathway enrichment analysis of SGI1027-induced genes in RCC10 cells. (C) RT-qPCR analysis of TNFSF10 , TNFRSF10A , TNFRSF10B , and TNFRSF10D mRNA levels in RCC10 cells treated with vehicle or SGI1027 for 2 days ( n = 3 biological replicates). (D and E) Immunoblot analysis of TRAIL, DR4, DR5, DcR2, pro-caspase-10, and cleaved caspase-10 (C-caspase-10) proteins in isogenic RCC10 cells treated with vehicle, SGI1027 (D and E, n = 2 biological replicates), MS1129 (E, n = 2 biological replicates), or decitabine (E, n = 2 biological replicates) for 2 or 7 days. (F) Global m5C levels in RCC10 cells treated with vehicle or SGI1027 for 2 days by ELISA assay ( n = 3 biological replicates). (G–J) MeDIP-qPCR assay in RCC10 cells treated with vehicle or SGI1027 for 2 days ( n = 3 biological replicates). (K–M) DNMT1, DNMT3A, and DNMT3B ChIP-qPCR assay in RCC10 cells ( n = 3 biological replicates). (N) Scheme of dDNMT-activated apoptotic pathway. Data represent mean ± SEM. p value was determined by bioinformatics with edgeR (A) or gene set enrichment analysis (B), unpaired 2-tailed Student’s t test (C and F), two-way ANOVA with Tukey’s test (G–I), and one-way ANOVA with Dunnett’s test (K–M). See also and .
Techniques Used: Quantitative RT-PCR, Western Blot, Enzyme-linked Immunosorbent Assay, Methylated DNA Immunoprecipitation, ChIP-qPCR
Figure Legend Snippet: dDNMT specifically kills patient-derived VHL -deficient ccRCC in mice (A) Tumor growth curves of VHL -deficient UTSW-PDX206, UTSW-PDX258, UTSW-PDX490, and UTSW-PDX26 in mice treated with vehicle (Veh) or SGI1027 for 10 days. (B) Tumor growth curves of VHL -WT UTSW-PDX416 and UTSW-PDX143 in mice treated with vehicle or SGI1027 for 10 days. (C) Kaplan-Meier survival curve of UTSW-PDX490-bearing mice ( n = 10 biological replicates). (D and E) Global m5C levels in UTSW-PDX206 (D) or UTSW-PDX258 (E) tumors harvested from mice after treatments by ELISA assay ( n = 5 biological replicates). (F) Immunoblot analysis of DNMT1, DNMT3A, DNMT3B, TRAIL, DR4, DR5, procaspase-10, C-caspase-3, and C-caspase-7 proteins in UTSW-PDX258 tumors harvested from mice after treatments ( n = 5 biological replicates). (G) Representative C-caspase-3 IHC in UTSW-PDX258 tumors. Scale bar, 100 μm. (H) Quantification of C-caspase-3-positive cells in (G) ( n = 5 biological replicates). (I) Immunoblot analysis of DNMT1, DNMT3A, DNMT3B, TRAIL, DR4, DR5, C-caspase-3, and VHL proteins in UTSW-PDX416 tumors harvested from mice after treatments ( n = 5 biological replicates). (J) Immunoblot analysis of DNMT1, DNMT3A, DNMT3B, and procaspase-10 proteins in UTSW-PDX206, UTSW-PDX258, and UTSW-PDX26 tumors ( n = 4–5 biological replicates). Data represent mean ± SEM. p value was determined by two-way ANOVA with Tukey’s test (A), log rank test (C), and unpaired 2-tailed Student’s t test (D, E, and H). See also and ; .
Techniques Used: Derivative Assay, Enzyme-linked Immunosorbent Assay, Western Blot
Related Articles
other:Article Title: Competition for cysteine acylation by C16:0 and C18:0 derived lipids is a global phenomenon in the proteome Article Snippet: Article Title: Competition for cysteine acylation by C16:0 and C18:0 derived lipids is a global phenomenon in the proteome. Article Snippet: Article Title: Competition for cysteine acylation by C16:0 and C18:0 derived lipids is a global phenomenon in the proteome Article Snippet: Article Title: JWA regulates TRAIL-induced apoptosis via MARCH8-mediated DR4 ubiquitination in cisplatin-resistant gastric cancer cells Article Snippet: All antibodies in this study were used as follows: anti-β-tubulin (1:1000, Huaan, Hangzhou, China); anti-JWA (1:500, AbMax, Beijing, China); anti-GAPDH (anti-glyceraldehyde 3-phosphate dehydrogenase), anti-his, and anti-Flag (1:2000, Beyotime, Shanghai, China); anti-MARCH8 and Western Blot:Article Title: Improving Targeted Delivery and Antitumor Efficacy of TRAIL through Fusion with a B7H3-Antagonistic Affibody. Article Snippet: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an attractive candidate for anticancer therapeutics due to its efficient pro-apoptotic activity against tumor cells and its well-tolerated safety profile.. However, the in vivo antitumor efficacy of TRAIL is often limited by its poor tumor targeting capacity.. Nowadays, the B7 homologue 3 (B7−H3) immune checkpoint has emerged as a promising target for tumor immunotherapy and drug delivery. |